Available online at www.sciencedirect.com

ScienceDirect



journal homepage: http://ees.elsevier.com/gendis/default.asp

VIEWS ON NEWS

Moving into a new era — SCIE coverage is the next rung on the ladder for *Genes & Diseases*

KEYWORDS

Genes & Diseases; Impact Factor; Molecular Medicine; Personalized Medicine; SCI; Translational Medicine

In a letter dated August 30, 2019 from Marian Hollingsworth, Director of Publisher Relations for the Web of Science Group Clarivate Analytics, Philadelphia, PA, USA, we were informed that *Genes & Diseases* has been selected for Science Citation Index Expanded (SCIE) coverage in the Genetics & Heredity and Biochemistry & Molecular Biology categories of the Clarivate Analytics products and services. Beginning with Volume 4 (1), 2017, *Genes & Diseases* will be indexed and abstracted in Science Citation Index Expanded (SCIE, also known as SciSearch®), Journal Citation Reports/ Science Edition, Current Contents®/Life Sciences, and Biological Abstracts. The first release of the journal's Impact Factor (IF) is anticipated in June 2020.

Launched in September 2014, *Genes & Diseases* is an international journal for molecular and translational medicine. The journal primarily focuses on publishing investigations on the molecular bases and experimental therapeutics of human diseases. In May 2018, *Genes & Diseases* formed a strategic alliance and partnership with the Association of Chinese Americans in Cancer Research (ACACR, Baltimore, MD, USA). *Genes & Diseases* publishes open access articles under the CC BY-NC-ND license, and is peer reviewed under the responsibility of the *Genes & Diseases* Editorial Board. *Genes & Diseases* was indexed by Scopus and the DOAJ in September 2016, by the Emerging

Peer review under responsibility of Chongqing Medical University.

Science Citation Index (ESCI) in November 2016, and by PubMed Central (PMC) in June 2018.

Genes & Diseases received a Scopus CiteScore of 3.41 in 2016, 4.74 in 2017, and 4.38 in 2018. In 2018, the journal's CiteScore rank was #14/91 (85%) in Genetics (clinical), #62/407 (84%) in Biochemistry, #80/375 (78%) in Molecular Biology, and #58/265 (78%) in Cell Biology, all of which were within the Q1 quartile ranking for the assigned categories.

We are deeply indebted to all of the contributing authors, the willing peer reviewers, the highly respected Editorial Board and the energetic Editorial Office staff members for their support and dedication to the success of the journal for the past five years. With the continuous support of our authors, reviewers and Editorial Board members, we are committed to making *Genes & Diseases* a high-impact SCI journal in the field of molecular and translational medicine.

T.-C. He, MD., PhD. The University of Chicago Medical Center, Molecular Oncology Laboratory/Dept of Orthopaedic Surgery, 5841 South Maryland Avenue. MC 3079, Chicago, IL, 60637, United States E-mail address: tche@uchicago.edu

> 13 October 2019 Available online 28 October 2019